Dr. Jeff Leighton (PhD), Chairman
Dr. Leighton, based in Boston, has 35 years of experience as a leading scientist and senior executive in pharmaceutical companies of various sizes. Among other positions, Dr. Leighton served as Glaxo’s Group Chairman for Cardio Vascular Disease and Glaxo Inc.’s Vice President of Pharmacology and Group Chairman of Metabolic Diseases. After leaving Glaxo in 1992, Dr. Leighton founded, managed, and directed multiple biotechnology companies including Genesis Pharmaceuticals, ICAgen (Nasdaq: ICGN), AdepoGenix, Inspire Pharmaceuticals (NASDAQ: ISPH) and others.
Prof. Ran Oren (MD)
Prof. Oren is a renowned specialist in gastroenterology and liver diseases, heading the Institute of Gastroenterology and Liver Diseases at Hadassah Hospital in Jerusalem, Israel. Prof. Oren is the former director of the Division of Internal Medicine at the Tel-Aviv Sourasky Medical Center in Tel Aviv, Israel. Prof. Oren has also served as Chair for the Israeli Society for Liver Diseases between 2007-2010.
Prof. Chezy Barenholz (PhD)
Prof. Barenholz is a renowned specialist in biochemistry, biophysics, nanotechnology and cancer, with 46 years of experience in research and development. Prof. Barenholz is the head of the Laboratory of Membrane and Liposome Research at the Department of Biochemistry, the Hebrew University–Hadassah Medical School, Jerusalem, Israel. Prof. Barenholz is the author of over 350 publications and the editor of academic journals and books. He is the co-inventor of over 30 patent families, two of which underlie Doxil™ for the treatment of breast and ovarian cancer. Doxil™ is the first liposomal drug and the first nano-medicine that was approved by the FDA.
Prof. Thomas Borody (MD)
Prof. Borody is the founder and manager of the Centre for Digestive Diseases in Sydney, Australia. Prof. Borody has vast experience in drug development projects as an inventor and investigator. Prof. Borody is considered to be the first physician to successfully formulate the triple therapy that would later become the gold standard for treating peptic ulcer disease caused by Helicobacter pylori infection. The triple therapy was invented in 1984 together with Dr. Barry Marshal and Dr. Robin Warren (who later received a Nobel prize for their research into Helicobacter pylori). Prof. Borody is the inventor of RedHill’s RHB-104 for the treatment of MAP in Crohn’s, which RedHill plans to advance into Phase II/III clinical trials.
Prof. Colin Blakemore (PhD)
Prof. Blakemore is a world renowned scientist from Oxford University, UK. He has authored hundreds of research publications and books. Prof. Blakemore has held several executive positions including head of the British Medical Research Council and president of the Biosciences Federation in the UK. He has received awards from many academic institutions worldwide for his scientific contribution, mainly in the area of neuroscience. In 2004 he won the BioIndustry Association Award for outstanding personal contribution to bioscience.
Dr. Jerry Rosenblatt (PhD)
Dr. Rosenblatt is a former Professor of Marketing, Associate Dean and Director of the MBA and Executive Development Programs at the John Molson School of Business, Concordia University, Montreal. He is a former Professor of Marketing and graduate of McGill University, one of Canada’s leading academic institutions. Dr. Rosenblatt was the Global Practice Leader, Forecasting and Opportunity Assessment practice for IMS Consulting (a leading healthcare research company), with over 25 years of experience as marketing advisor to pharmaceutical companies.
Dr. Werner Tschollar (MD)
Dr. Tschollar, based in Switzerland, is a former Senior Vice President, Worldwide R&D at Novartis Consumer Pharmaceuticals. Dr. Tschollar led and held senior executive positions in several biopharmaceutical companies including, among others, Bristol-Myers Squibb/Princeton, Schering-Plough, Xytis, Inc. and Neurim Pharmaceuticals Ltd.
Dr. Joshua Schein (PhD)
Dr. Schein, based in New York, has been involved in the founding, financing and managing of pharmaceutical companies since 1991, including Lev Pharmaceuticals which was acquired by ViroPharma (NASDAQ:VPHM) for $443 3 million. Dr. Schein has held senior executive positions in US companies, serving as CEO of SIGA Technologies (NASDAQ: SIGA) and Lev Pharmaceuticals.
Mr. Abe Schwartz
Mr. Schwartz based in Toronto, is the founder and president of Schwartz Technologies Corporation and acts as an advisor to Covalon Technologies. Mr. Schwartz founded and held executive positions in various companies, including, among others, President and CEO of Cedara Software Corp. Mr. Schwartz has over 35 years of experience in launching products, R&D, international distribution agreements, re-organization in large scale corporations, financing and M&A.